<DOC>
	<DOCNO>NCT00549653</DOCNO>
	<brief_summary>This study conduct provide initial safety tolerability data well provide PK data potential interaction GW856553 rosuvastatin co-administered healthy male adult</brief_summary>
	<brief_title>A Study Investigating Blood Concentrations Of Rosuvastatin When Co-administered With GW856553 In Healthy Men</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Inclusion criterion : Healthy adult male , 1855 year age , inclusive 50Kg &gt; body weight &lt; 120Kg Body Mass Index ( BMI ) : 1930 Must within 20 % ideal weight base height body frame Exclusion criterion : Any medical history clinically relevant abnormality identify screen medical examination , vital sign measurement , 12lead ECG record and/or clinical laboratory examination deem principal investigator and/or medical monitor make subject ineligible inclusion safety concern . Subjects rheumatoid arthritis , connective tissue disorder condition know associate chronic inflammation ( e.g . Inflammatory Bowel Disease ) . Positive HIV antibody , Hepatitis B surface antigen , Hepatitis C antibody , chronic hepatic disorder screen . Subjects chronic infection gingivitis , periodontitis , prostatitis , gastritis , urinary track infection , active disease , include tuberculosis history active tuberculosis . Subjects acute infection , symptom suggestive sinusitis significant trauma ( burn , fracture ) . History alcohol consumption exceed , average , 14 drinks/week men ( 1 drink = 5 ounce wine 12 ounce beer 1.5 ounce 80 proof distil spirit ) within 6 month screen . Positive urine drug ( include cotinine ) and/or alcohol screening . A history smoking within 3 month prior screen . Use prescription nonprescription drug , include ( limited ) vitamin , herbal dietary supplement ( include St. John 's Wort ) within 7 day ( 14 day drug potential drug inducer ) 5 halflives ( whichever longer ) prior first dose study medication . An exception acetaminophen allow dos â‰¤ 2g/day . Participation clinical study subject receive drug new chemical entity within 30 day 5 halflives , twice duration biological effect drug ( whichever longer ) prior first dose study medication . The subject expose four new chemical entity within 12 month prior first day dose . Consumption fruit juice ( include grapefruit juice ) within 7 day prior first dose study medication . A history cholecystectomy biliary tract disease include history liver disease elevate liver function test know unknown etiology . History increase liver function test ( ALT , AST ) upper limit normal past 6 month and/or liver function test ( bilirubin , ALT , AST ) upper limit normal Screening . A known history Gilbert 's Syndrome . History myopathy rhabdomyolysis . QTc interval &gt; 450msec . An unwillingness male subject abstain sexual intercourse pregnant lactating woman ; unwillingness male subject use condom/spermicide addition female partner use another form contraception , : intrauterine devise ( IUD ) , diaphragm spermicide , oral contraceptive , injectable progesterone , subdermal implant tubal ligation , woman could become pregnant first dose study medication completion followup procedure . Donation blood excess 500 mL within 56 day prior dose . History sensitivity heparin heparininduced thrombocytopenia . Hypersensitivity rosuvastatin component rosuvastatin formulation utilise study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>GW856553 ,</keyword>
	<keyword>drug-drug interaction ,</keyword>
	<keyword>rosuvastatin</keyword>
</DOC>